Long-term Effects of Erythropoietin on Platelet Serotonin Storage and Platelet Aggregation in Hemodialysis Patients with Reference to Ketanserin Treatment

Borawski, Jacek; Rydzewski, Andrzej; Pawlak, Krystyna; Azzadin, A; Buczko, Włodzimierz; Myśliwiec, Michał

doi:10.1016/s0049-3848(98)00031-0

Cited by 8 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other limitations of this study include the relatively small sample sizes (and the associated possibility of a type II error), study groups that were quite different in demographic composition (i.e., age and race), and the previously scrutinized (rather than newly scrutinized) groups of normal comparison subjects and patients with major depression. Furthermore, the dialysis patients and the thoracic aortic patients received medications that might increase, e.g., erythro-poietin [Borwaski et al, 1998;Stohlawetz, 2000], or reduce platelet stimulation and secretion, e.g., angiotensin converting enzyme inhibitors, antilipid agents, benzodiazepines, beta-or calcium channel blockers, or nitrates.…”

Section: Discussionmentioning

confidence: 99%

Platelet activation and secretion in patients with major depression, thoracic aortic atherosclerosis, or renal dialysis treatment

et al. 2002

View full text Add to dashboard Cite

Relatively little is known concerning the magnitude of alterations of platelet activation and secretion markers of patients with major depression when compared to patients at increased risk for, or with current, clinically significant atherosclerosis. Markers of in vivo platelet stimulation and secretion were measured under basal conditions in normal comparison subjects (n = 12) and three patient groups: patients diagnosed with DSM-IV major depression (n = 15), dialysis-dependent patients (n = 12), and patients with severe thoracic aortic atherosclerosis (n = 10). In comparison to normal comparison subjects, depressed patients and patients with thoracic aortic atherosclerosis exhibited the greatest platelet stimulation as detected by increased anti-LIBS platelet binding. Dialysis-dependent patients exhibited the highest plasma concentrations of the renally-excreted platelet-specific secretion protein, beta-thromboglobulin. This study extends previous observations of increased platelet activation in patients with major depression and documents similar alterations in patients with transesophageal echocardiography (TEE)-documented thoracic aortic atherosclerosis. Future studies will determine whether the magnitude of platelet stimulation and secretion in patients with comorbid depression and atherosclerotic aortic disease is greater than that observed in nondepressed patients with atherosclerotic aortic disease or major depression alone. These findings provide further evidence for either increased platelet activation and/or intrinsic heightened platelet reactivity as one of the biological substrates underlying the increased risk of depressed patients for cardiovascular disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Platelet activation and secretion in patients with major depression, thoracic aortic atherosclerosis, or renal dialysis treatment

et al. 2002

View full text Add to dashboard Cite

show abstract

“…We assumed that platelets colliding in higher hematocrits could release more of the vWF stored within their α-granules and thereby aggregate more intensively. Recently, we found RIPA WB to increase early [34]and steadily [35]during EPO treatment. The lack of differences between the EPO-treated and untreated patients in the present study could be partially due to the comparable hematocrits and platelet counts.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Different Assays for von Willebrand Factor in Hemodialysis Patients

Borawski

Pawlak²,

Myśliwiec³

2000

Pathophysiol Haemos Thromb

Self Cite

View full text Add to dashboard Cite

Von Willebrand factor (vWF) abnormalities are involved in the hemostatic disturbances of uremia. Studies of vWF in both anemic and recombinant erythropoietin (EPO)-treated maintenance hemodialysis (HD) patients have given inconsistent results that could be partially dependent on the methodology. Therefore, the reciprocal relationships between four different vWF assays were studied in HD patients in relation to EPO therapy. Plasma vWF activity measured by ELISA using monoclonal antibodies against platelet glycoprotein (GP) Ibα (vWF:Act), plasma vWF antigen concentration by ELISA employing polyclonal antihuman vWF antibodies (vWF:Ag), and functional vWF activity by ristocetin-induced platelet aggregation (RIPA) in both platelet-rich plasma (PRP) and whole blood were studied in 70 HD patients. In the whole group, no correlations between these assays were found. In the non-EPO patients (n = 32), vWF:Act was correlated with vWF:Ag (r = 0.504, p = 0.003) but not with vWF activity by RIPA in PRP. In the EPO-treated patients (n = 38), vWF:Act was higher than in the untreated ones (p = 0.001), and vWF:Ag was related to the whole-blood RIPA (r = 0.386, p = 0.016). In conclusion, the platelet GP Ibα-binding epitope of the vWF molecule assessed by vWF:Act ELISA is intact in HD patients. However, this assay does not reflect the functional vWF activity as measured by RIPA in PRP. In EPO-treated patients, the GP Ibα-binding domains of vWF are more available but the plasmatic vWF monomers are neither more numerous by vWF:Ag ELISA nor more hemostatically active by RIPA PRP. The whole blood RIPA test has some potential for the quantification of vWF monomers in EPO-treated HD patients.

show abstract

“…The research and development of these medicines aims to treat human diseases effectively. Anti-agglutinate medicines of blood platelet include ketanserin, 3) milrinone 4) and ticlopidine. 5) Ketanserin produced a decrease in ristocetin-induced platelet aggregation, fibrinogen and prolongation of the bleeding time.…”

mentioning

confidence: 99%

Synthesis and Structural Pattern Recognition of 5-(2'-Alkoxycarbonyl-substituted phenoxy)furfural Derivatives

Chang

2009

CHEMICAL & PHARMACEUTICAL BULLETIN

View full text Add to dashboard Cite

Long-term Effects of Erythropoietin on Platelet Serotonin Storage and Platelet Aggregation in Hemodialysis Patients with Reference to Ketanserin Treatment

Cited by 8 publications

References 34 publications

Platelet activation and secretion in patients with major depression, thoracic aortic atherosclerosis, or renal dialysis treatment

Platelet activation and secretion in patients with major depression, thoracic aortic atherosclerosis, or renal dialysis treatment

Comparison of Different Assays for von Willebrand Factor in Hemodialysis Patients

Synthesis and Structural Pattern Recognition of 5-(2'-Alkoxycarbonyl-substituted phenoxy)furfural Derivatives

Contact Info

Product

Resources

About